Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
|
|
Molecular Templates, Inc. (MTEM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/11/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Molecular Templates, Inc",
"Molecular Templates Announces 1-for-15 Reverse Stock Split AUSTIN, Texas, August 11, 2023 - Molecular Templates, Inc., , a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company's common stock at a special meeting of the Company held on August 11, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Friday, August 11, 2023. The Company's common stock will open for trading under a new CUSIP number 608550 208 on The Nasdaq Capital Market on August 14, 2023, on a split-adjusted basis under the current ticker symbol “MTEM...." |
|
| 08/10/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update AUSTIN, Texas, Aug. 10, 2023 -- Molecular Templates, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies , to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the second quarter of 2023. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, “ETBs represent a novel approach to the treatment of cancer with differentiated biology and unique mechanisms of action. We expect to see substantial data across all three of our clinical programs with updates throughout this year and into ..." |
|
| 08/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/31/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/18/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.4% stake in Molecular Templates, Inc. |
| 07/18/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Pre-Funded Warrant to Purchase Common Stock",
"Form of Common Warrant",
"Securities Purchase Agreement",
"Molecular Templates Announces Up to $40 Million Private Placement Offering AUSTIN, Texas, July 13, 2023 — Molecular Templates, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies , to create novel therapies with potent differentiated mechanisms of action for cancer, announced today it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $40 million in gross proceeds to MTEM through a private placement in two tranches. The financing is being led by existing investor BVF Partners LP and includes existing investors BB Biotech AG and Adage Capital Management, and other leading institutional investors. The purchase is comp..." |
|
| 06/30/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/03/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/02/2022 |
8-K
| Quarterly results |
| 12/01/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 09/01/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/27/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2022 |
8-K
| Quarterly results|
Docs:
|
"Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results AUSTIN, Texas, March 28, 2022 -- Molecular Templates, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies , today reported financial results for the fourth quarter of 2021. “2022 is off to a very promising start, following a number of important developments across our pipeline of ETBs in 2021,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. “We continue to see differentiated pharmacodynamic effects and evidence of antigen seeding with MT-6402 with additional data expected throughout 2022. We continue dose finding for the MT-5111 and MT-0169 programs with clinical dat..." |
|
| 03/29/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
|
|
|